Session » Vasculitis – ANCA-Associated Poster I

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2630

A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2622

A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2623

Abnormality of Percentages and Absolute Numbers of CD4+ Memory and Regulatory T Subset Cells in ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2635

Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2634

ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

9:00AM-11:00AM: Abstract Number: 2642

ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA

9:00AM-11:00AM: Abstract Number: 2621

Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis

9:00AM-11:00AM: Abstract Number: 2627

Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2626

Cell-free Mitochondrial DNA Levels in Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2632

Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center

9:00AM-11:00AM: Abstract Number: 2641

Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 2636

Cluster Analysis for Classification of Japanese Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Subgroup Analysis of Nationwide Cohort Studies

9:00AM-11:00AM: Abstract Number: 2643

Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre

9:00AM-11:00AM: Abstract Number: 2624

Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial

9:00AM-11:00AM: Abstract Number: 2639

Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2620

Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model

9:00AM-11:00AM: Abstract Number: 2633

Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis

9:00AM-11:00AM: Abstract Number: 2631

Increased Risk of Acute Coronary Artery Disease and Ischemic Stroke in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2628

Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center

9:00AM-11:00AM: Abstract Number: 2640

Performance of Berden’s Classification and ANCA Renal Risk Score for the Prediction of End-Stage Renal Disease in ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2625

Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement

9:00AM-11:00AM: Abstract Number: 2619

Rituximab for Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of Observational Studies

9:00AM-11:00AM: Abstract Number: 2638

The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2629

Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2637

Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].